New study targets rare Virus-Driven inflammatory syndrome
NCT ID NCT01419561
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 6 times
Summary
This study looks at a newly recognized disease called KSHV Inflammatory Cytokine Syndrome (KICS), caused by a virus that can also lead to certain cancers. Researchers aim to learn more about the disease and test experimental treatments, including antiviral and chemotherapy drugs, in people with KICS. The study involves regular check-ups, blood tests, and imaging to track the disease and response to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zidovudine, liposomal doxorubicin, and valganciclovir (antiviral and chemotherapy drugs)
- What this could lead to
- If successful, this study could lead to better understanding and treatment options for KICS, a severe inflammatory condition caused by a virus.
- What could go wrong
- This is an early-phase study with a small number of participants, so results may not apply to everyone. The treatments can have side effects, and it's unclear if they will effectively control the disease long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HHV-8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.